Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Epigenetic control of gene expression is critical for normal fetal development. However, chromatin-related mechanisms that activate bone-specific programs during osteogenesis have remained underexplored. Therefore, we investigated the expression profiles of a large cohort of epigenetic regulators (>300) during osteogenic differentiation of human mesenchymal cells derived from the stromal vascular fraction of adipose tissue (AMSCs). Molecular analyses establish that the polycomb group protein EZH2 (enhancer of zeste homolog 2) is down-regulated during osteoblastic differentiation of AMSCs. Chemical inhibitor and siRNA knockdown studies show that EZH2, a histone methyltransferase that catalyzes trimethylation of histone 3 lysine 27 (H3K27me3), suppresses osteogenic differentiation. Blocking EZH2 activity promotes osteoblast differentiation and suppresses adipogenic differentiation of AMSCs. High throughput RNA sequence (mRNASeq) analysis reveals that EZH2 inhibition stimulates cell cycle inhibitory proteins and enhances the production of extracellular matrix proteins. Conditional genetic loss of Ezh2 in uncommitted mesenchymal cells (Prrx1-Cre) results in multiple defects in skeletal patterning and bone formation, including shortened forelimbs, craniosynostosis, and clinodactyly. Histological analysis and mRNASeq profiling suggest that these effects are attributable to growth plate abnormalities and premature cranial suture closure because of precocious maturation of osteoblasts. We conclude that the epigenetic activity of EZH2 is required for skeletal patterning and development, but EZH2 expression declines during terminal osteoblast differentiation and matrix production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Epigenetics and gene expression
Gibney, E. R., & Nolan, C. M. (2010) · Heredity · doi:10.1038/hdy.2010.54 · Cited by 1,109
An Abundance of Ubiquitously Expressed Genes Revealed by Tissue Transcriptome Sequence Data
Ramsköld, D., Wang, E. T., Burge, C. B., & Sandberg, R. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000598 · Cited by 820
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450 · cited 1×
“These findings are particularly interesting, because epigenetic drugs are currently used in the treatment of various cancers (53, 54) and other medical conditions including mood disorders and epilepsy (5, 55), Alzheimer’s disease (56), pain (57), and autoimmune diseases (58).”
BackgroundLópez-Rovira, T., Chalaux, E., Massagué, J., Rosa, J. L., & Ventura, F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106826200 · Cited by 285
Epigenetic regulation in the pathophysiology of Alzheimer's disease
Chouliaras, L., Rutten, B. P. F., Kenis, G., Peerbooms, O., Visser, P. J., Verhey, F., van Os, J., Steinbusch, H. W. M., & van den Hove, D. L. A. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.002 · Cited by 262 · cited 1×
“These findings are particularly interesting, because epigenetic drugs are currently used in the treatment of various cancers (53, 54) and other medical conditions including mood disorders and epilepsy (5, 55), Alzheimer’s disease (56), pain (57), and autoimmune diseases (58).”
BackgroundUpdate in new anabolic therapies for osteoporosis
Canalis, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2677 · Cited by 85
Cited by
Programmed cell senescence in skeleton during late puberty
Li, C., Chai, Y., Wang, L., Gao, B., Chen, H., Gao, P., Zhou, F.-Q., Luo, X., Crane, J. L., Yu, B., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01509-0 · Cited by 92
Adamik, J., Jin, S., Sun, Q., Zhang, P., Weiss, K. R., Anderson, J. L., Silbermann, R., Roodman, G. D., & Galson, D. L. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0242-t · Cited by 73
“(47) reported that human stromal cells from the vascular fraction of adipose tissue displayed enhanced OB differentiation if treated with EZH2 inhibitor or shRNA.”
BackgroundEpigenetic control of mesenchymal stem cells orchestrates bone regeneration
Wang, X., Yu, F., & Ye, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1126787 · Cited by 24
“Moreover, this developmental abnormality of the skeletal system may be related to the diminished MSC proliferation and promotion of osteogenic differentiation triggered by the deletion of EZH2 in MSCs (11).”
BackgroundTranscriptomic Signatures of Single-Suture Craniosynostosis Phenotypes
Lapehn, S., Gustafson, J. A., Timms, A. E., Cunningham, M. L., & Paquette, A. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065353 · Cited by 3
Metadata
- Authors
- Dudakovic, A., Camilleri, E. T., Xu, F., Riester, S. M., McGee-Lawrence, M. E., Bradley, E. W., Paradise, C. R., Lewallen, E. A., Thaler, R., Deyle, D. R., Larson, A. N., Lewallen, D. G., Dietz, A. B., Stein, G. S., Montecino, M. A., Westendorf, J. J., & van Wijnen, A. J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 290
- Issue
- 46
- Pages
- 27604-27617
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2177193863
- Cited by
- 178
- References
- 10
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.